Lv2
200 积分 2025-10-26 加入
Membranous nephropathy
21天前
已完结
KDIGO provided recommendations on SGLT2 inhibitors and nonsteroidal MRAs in patients with diabetes and CKD
30天前
已完结
Some Points for the KDIGO 2021 Guideline for Prophylactic Anticoagulation in Membranous Nephropathy: Is It Clear Enough for Us to Follow?
30天前
已关闭
Novel approaches to primary membranous nephropathy: Beyond the KDIGO guidelines
1个月前
已完结
Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stage
1个月前
已完结
Complement activation and effector pathways in membranous nephropathy
1个月前
已完结
Membranous nephropathy
1个月前
已完结
Antigens in membranous nephropathy: discovery and clinical implications
1个月前
已完结
Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy
1个月前
已完结
Novel treatment options in rituximab-resistant membranous nephropathy patients
1个月前
已完结
皖公网安备34019202002308
